Literature DB >> 20460535

Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib.

Siquan Chen1, Jonathan L Blank, Theodore Peters, Xiaozhen J Liu, David M Rappoli, Michael D Pickard, Saurabh Menon, Jie Yu, Denise L Driscoll, Trupti Lingaraj, Anne L Burkhardt, Wei Chen, Khristofer Garcia, Darshan S Sappal, Jesse Gray, Paul Hales, Patrick J Leroy, John Ringeling, Claudia Rabino, James J Spelman, Jay P Morgenstern, Eric S Lightcap.   

Abstract

Multiple pathways have been proposed to explain how proteasome inhibition induces cell death, but mechanisms remain unclear. To approach this issue, we performed a genome-wide siRNA screen to evaluate the genetic determinants that confer sensitivity to bortezomib (Velcade (R); PS-341). This screen identified 100 genes whose knockdown affected lethality to bortezomib and to a structurally diverse set of other proteasome inhibitors. A comparison of three cell lines revealed that 39 of 100 genes were commonly linked to cell death. We causally linked bortezomib-induced cell death to the accumulation of ASF1B, Myc, ODC1, Noxa, BNIP3, Gadd45alpha, p-SMC1A, SREBF1, and p53. Our results suggest that proteasome inhibition promotes cell death primarily by dysregulating Myc and polyamines, interfering with protein translation, and disrupting essential DNA damage repair pathways, leading to programmed cell death. Copyright 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20460535     DOI: 10.1158/0008-5472.CAN-09-4428

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.

Authors:  Sudha Mannava; DaZhong Zhuang; Jayakumar R Nair; Rajat Bansal; Joseph A Wawrzyniak; Shoshanna N Zucker; Emily E Fink; Kalyana C Moparthy; Qiang Hu; Song Liu; Lawrence H Boise; Kelvin P Lee; Mikhail A Nikiforov
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

2.  RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Authors:  S E Martin; Z-H Wu; K Gehlhaus; T L Jones; Y-W Zhang; R Guha; S Miyamoto; Y Pommier; N J Caplen
Journal:  Curr Cancer Drug Targets       Date:  2011-10       Impact factor: 3.428

3.  Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.

Authors:  Chungyee Leung-Hagesteijn; Natalie Erdmann; Grace Cheung; Jonathan J Keats; A Keith Stewart; Donna E Reece; Kim Chan Chung; Rodger E Tiedemann
Journal:  Cancer Cell       Date:  2013-09-09       Impact factor: 31.743

Review 4.  Proteasome inhibitors: an expanding army attacking a unique target.

Authors:  Alexei F Kisselev; Wouter A van der Linden; Herman S Overkleeft
Journal:  Chem Biol       Date:  2012-01-27

5.  Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.

Authors:  Mohammad A Shahshahan; Maureen N Beckley; Ali R Jazirehi
Journal:  Am J Cancer Res       Date:  2011-08-23       Impact factor: 6.166

6.  Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.

Authors:  Marc A Weniger; Edgar G Rizzatti; Patricia Pérez-Galán; Delong Liu; Qiuyan Wang; Peter J Munson; Nalini Raghavachari; Therese White; Megan M Tweito; Kieron Dunleavy; Yihong Ye; Wyndham H Wilson; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2011-06-28       Impact factor: 12.531

7.  Impact of Losing hRpn13 Pru or UCHL5 on Proteasome Clearance of Ubiquitinated Proteins and RA190 Cytotoxicity.

Authors:  Vasty Osei-Amponsa; Vinidhra Sridharan; Mayank Tandon; Christine N Evans; Kimberly Klarmann; Kwong Tai Cheng; Justin Lack; Raj Chari; Kylie J Walters
Journal:  Mol Cell Biol       Date:  2020-08-28       Impact factor: 4.272

8.  Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.

Authors:  Slavica Brnjic; Magdalena Mazurkiewicz; Mårten Fryknäs; Chao Sun; Xiaonan Zhang; Rolf Larsson; Pádraig D'Arcy; Stig Linder
Journal:  Antioxid Redox Signal       Date:  2013-10-17       Impact factor: 8.401

Review 9.  The Tao of myeloma.

Authors:  Lawrence H Boise; Jonathan L Kaufman; Nizar J Bahlis; Sagar Lonial; Kelvin P Lee
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

10.  Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.

Authors:  Justin T Babcock; Hoa B Nguyen; Yujun He; Jeremiah W Hendricks; Ronald C Wek; Lawrence A Quilliam
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.